An interventional study of unilateral laparoscopic adrenalectomy and standard medical treatment in Resistant Hypertension and Adrenal Disease, sponsored by Chinese Academy of Medical Sciences, Fuwai Hospital. Status unknown at 3 sites in China. Per ClinicalTrials.gov, last updated 2018-05-24.
Sponsored by Chinese Academy of Medical Sciences, Fuwai Hospital · Not applicable, Interventional, and Treatment
ULARH is a 2-arm, prospective, open-labeled, multi-center randomized clinical trial.The purpose of this study is to compare the effectiveness of medical treatment and unilateral laparoscopic adrenalectomy for resistant hypertension in patients diagnosed with adrenal disease based on imaging tools.Relative ratio of end-point events occurence in three years is considered as primary outcome. Furthermore, we will exploit clinical factors which could indicate a favorable outcome in participants who accepted surgical treatment in this study.
Resistant hypertension is a clinical condition characterized by the presence of BP values above the recommended limits of the reference values(BP>140/90 mmHg in hypertensive patients), despite the adherence to appropriate life style changes and to a drug therapy of at least three classes of drugs, one of which is represented by a diuretic, in adequate doses. Several small-sample studies suggest the prevalence of resistant hypertension is about 5-30% in Chinese population. Uncontrolled blood pressure elevation attributes to a higher incidence of stroke, heart failure, chronic renal disease, dementia and cardiovascular deaths. Improving the management of resistant hypertension is a constantly tricky problem in hypertension clinical practice.
Compared with patients whose blood pressure level are more easily to get controlled, patients diagnosed with resistant hypertension presented a higher risk of adrenal anomaly when screened by imaging tools. Current clinical practice guidance recommend unilateral laparoscopic adrenalectomy as a preferable treatment merely for adrenal incidentalomas with over hormone secreting like cortisol or aldosterone, or a high likelihood of malignance. Among patients who meet above surgery indication, the ratio of cure for hypertension varies from approximately 30 to 80%. However, in recent years, there are growing evidence showed that hypertensive patients diagnosed with adrenal disease based on imaging tools also gain much benefit from adrenalectomy even if there is no evidently abnormal hormone secretion. Last year, a prospective cohort study published on \<Ann Intern Med> suggested that "nonfunctional" adrenal tumors associate with increased diabetes risk. These studies prompt a re-assessment of the classification of benign adrenal tumors as "non-functional"and their potential damage.
In a retrospective study conducted by our group in early period to evaluate the effect of surgery treatment in resistant hypertensive patients, we found one third of resistant hypertensive patients were cured as well as another one third get improved after unilateral laparoscopic adrenalectomy. Thus, we designed this study, expecting a further and more detailed perception of the relationship between resistant hypertension and adrenal anomaly.
24 studies on the registry are indexed under Adrenal Gland Diseases; 9 are open to participants now.
This study's planned enrollment of 1,000 is above the median of 83 across 11 interventional studies indexed under Adrenal Gland Diseases.
Browse Adrenal Gland Diseases studies →Chinese Academy of Medical Sciences, Fuwai Hospital is the lead sponsor of 146 studies on the registry; 50 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
subjects allocated in this group will be given unilateral laparoscopic adrenalectomy as treatment.
Procedure: unilateral laparoscopic adrenalectomy
subjects allocated in standard medical treatment group will be given conservative medicine treatment.
Drug: standard medical treatment
unilateral laparoscopic adrenalectomy is a kind of minimally invasive surgery commonly operated in patients diagnosed with adrenal diseases with a high likelihood of malignance or surplus hormone secretion.
Also known as: standard medical treatment
standard medical treatment: detailed medicine strategy chosen for each patient will be associated with their own conditions based on current guidance recommendations.
Also known as: unilateral laparoscopic adrenalectomy
A composite of end-point events
A composite end-point comprised of myocardial infarction(MI), congestive heart failure, cerebrovascular event, end stage renal disease, death.
Time frame: 3 year
Major coronary events
Major coronary events comprised of myocardial infarction (MI), hospitalization for unstable angina or acute decompensated heart failure, coronary revascularization (percutaneous coronary intervention \[PCI\], coronary artery bypass grafting \[CABG\]), and death from cardiovascular causes.
Time frame: 3 years
First occurrence of symptomatic stroke (ischemic or hemorrhagic, fatal or nonfatal)
First occurrence of symptomatic stroke (ischemic or hemorrhagic, fatal or nonfatal)
Time frame: 3 years
All-cause death
All-cause death
Time frame: 3 years
Cardiovascular death
Cardiovascular death
Time frame: 3 years
myocardial infarction
myocardial infarction
Time frame: 3 years
Hospitalization for unstable angina
Hospitalization for unstable angina
Time frame: 3 years
Hospitalization for acute decompensated heart failure
Hospitalization for acute decompensated heart failure
Time frame: 3 years
coronary revascularization (percutaneous coronary intervention [PCI], coronary bypass grafting [CABG])
coronary revascularization (percutaneous coronary intervention \[PCI\], coronary bypass grafting \[CABG\])
Time frame: 3 years
First occurence of diabetes mellitus
First occurence of diabetes mellitus
Time frame: 3 years
Decline in cognitive function
Decline in cognitive function includes sensory disturbance, memory disorders and thinking disorders, which is assessed by mini-mental state examination (MMSE)
Time frame: 3 years
Decline in renal functio or development of end stage renal disease (ESRD)
Decline in renal function is assessed by any of the following: (1) For patients with chronic kidney disease (eGFR\<60 ml per minute per 1.73 m2) at baseline, the renal outcome was a composite of a decrease in the eGFR of 50% or more (confirmed by a subsequent laboratory test) or the development of EDRD requiring long-term dialysis or kidney transplantation; or (2) For participants without chronic kidney disease at baseline, the renal outcome was defined by a decreased in the eGFR of 30% or more to a value of less than 60 ml per minute per 1.73 m2.
Time frame: 3 years
Major artery function changes
Major artery function changes are assessed by a composite of decrease in the ankle branchial index \[ABI\], brachial-ankle pulse wave velocity(baPWV),or brachial artery flow-mediated dilation \[FMD\]. ABI and baPWV, well-established non-invasive techniques fr evaluating obstruction and stiffness of peripheral artery respectively, are considered for the purposes of cardiovascular risk assessment. ABI is the ratio of average systolic blood pressure measured in brachial/ankle, and an ABI between and including 0.9 and 1.2 is considered normal, while a lesser than 0.9 indicates arterial disease. The unit measure of baPWV value is cm per second. FMD serves as an index of nitric oxide (NO)-mediated endothelium-dependent vasodialator function in humans and is regarded as a surrogate marker of cardiovascular disease.
Time frame: 3 years
Plan to share: Undecided — Undecided yet
Start is estimated for Dec 2018; primary completion for Oct 2020, 22 months later.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in May 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Chinese Academy of Medical Sciences, Fuwai Hospital →